Citations

Clear

949 citation(s) found for "Li, Bryan".

More Than Likes and Tweets: Creating Social Media Portfolios for Academic Promotion and Tenure
Cabrera, Daniel , Vartabedian, Bryan S., Spinner, Robert J. , Jordan, Barbara L., Aase, Lee , Timimi, Farris K. , Cabrera, Daniel

Mayo Clinic

Journal of Graduate Medical Education | August 15, 2017 | Volume: 9 | Issue: 4 | Pages: 421-425

10.4300/jgme-d-17-00171.1 | PMID 28824752 Get It

The Timing of Hip Arthroscopy After Intra‐articular Hip Injection Affects Postoperative Infection Risk
Coleman, Struan H. , Kelly, Bryan T. , Werner, Brian C. , Wang, Dean , Camp, Christopher L. , Ranawat, Anil S.

Mayo Clinic

Arthroscopy | August 8, 2017 | Volume: 33 | Issue: 11 | Pages: 1988

10.1016/j.arthro.2017.06.037 | PMID 28800918 Get It

Purpose To evaluate the association of preoperative intra‐articular hip injection with surgical site infection after hip arthroscopy. Methods A large administrative database was used to identify all patients undergoing hip arthroscopy from 2007 to 2015 within a single private insurer and from 2005 to 2012 within Medicare in the United States. Those that received an ipsilateral preoperative intra‐articular hip injection were identified. The patients were then divided into the following groups based on the interval between preoperative injection and ipsilateral hip arthroscopy: (1) <3 months, (2) 3 to 6 months, and (3) 6 to 12 months. These groups were compared to a control group composed of patients with no history or a remote history (>12 months) of preoperative hip injection. Patients developing a surgical site infection within 6 months following hip arthroscopy were identified using International Classification of Diseases, Ninth Revision, and Current Procedural Terminology codes associated with infection. Groups were compared using a multivariate logistic regression analysis to control for age, gender, body mass index, smoking status, alcohol usage, and multiple medical comorbidities including diabetes mellitus, hemodialysis use, inflammatory arthritis, and peripheral vascular disease. Results In total, 19% of privately insured and 6% of Medicare patients received a hip injection within 12 months of hip arthroscopy. The overall infection rate in privately insured and Medicare patients was 1.19% and 1.10%, respectively. Preoperative hip injection within 3 months of surgery was associated with a significantly higher risk of postoperative infection versus controls (2.16%, odds ratio [OR] 6.1, P < .001, for privately insured group; 2.80%, OR 1.99, P = .037, for Medicare group). In contrast, preoperative hip injection given after more than 3 months of surgery was not associated with an increased risk of postoperative infection versus controls. Conclusions Risk of infection after hip arthroscopy increased when preoperative intra‐articular hip injections were given within 3 months of surgery. Level of Evidence Level III, retrospective comparative study.
Comprehensive biomechanical analysis of three reconstruction techniques following total sacrectomy: an in vitro human cadaveric model
Macki, Mohamed, Ramos, Rafael De la Garza , Murgatroyd, Ashley A., Mullinix, Kenneth P., Cunningham, Bryan W. , McCutcheon, Brandon A., Bydon, Mohamad , Gokaslan, Ziya L. , Sun, Xiaolei , De la Garza Ramos, Rafael

Mayo Clinic

Journal of Neurosurgery: Spine | August 4, 2017 | Volume: 27 | Issue: 5 | Pages: 570-577

10.3171/2017.2.spine161128 | PMID 28777063 Get It

OBJECTIVEAggressive sacral tumors often require en bloc resection and lumbopelvic reconstruction. Instrumentation failure and pseudarthrosis remain a clinical concern to be addressed. The objective in this study was to compare the biomechanical stability of 3 distinct techniques for sacral reconstruction in vitro.METHODSIn a human cadaveric model study, 8 intact human lumbopelvic specimens (L2–pelvis) were tested for flexion-extension range of motion (ROM), lateral bending, and axial rotation with a custom-designed 6-df spine simulator as well as axial compression stiffness with the MTS 858 Bionix Test System. Biomechanical testing followed this sequence: 1) intact spine; 2) sacrectomy (no testing); 3) Model 1 (L3–5 transpedicular instrumentation plus spinal rods anchored to iliac screws); 4) Model 2 (addition of transiliac rod); and 5) Model 3 (removal of transiliac rod; addition of 2 spinal rods and 2 S-2 screws). Range of motion was measured at L4–5, L5–S1/cross-link, L5–right ilium, and L5–left ilium.RESULTSFlexion-extension ROM of the intact specimen at L4–5 (6.34° ± 2.57°) was significantly greater than in Model 1 (1.54° ± 0.94°), Model 2 (1.51° ± 1.01°), and Model 3 (0.72° ± 0.62°) (p < 0.001). Flexion-extension at both the L5–right ilium (2.95° ± 1.27°) and the L5–left ilium (2.87° ± 1.40°) for Model 3 was significantly less than the other 3 cohorts at the same level (p = 0.005 and p = 0.012, respectively). Compared with the intact condition, all 3 reconstruction groups statistically significantly decreased lateral bending ROM at all measured points. Axial rotation ROM at L4–5 for Model 1 (2.01° ± 1.39°), Model 2 (2.00° ± 1.52°), and Model 3 (1.15° ± 0.80°) was significantly lower than the intact condition (5.02° ± 2.90°) (p < 0.001). Moreover, axial rotation for the intact condition and Model 3 at L5–right ilium (2.64° ± 1.36° and 2.93° ± 1.68°, respectively) and L5–left ilium (2.58° ± 1.43° and 2.93° ± 1.71°, respectively) was significantly lower than for Model 1 and Model 2 at L5–right ilium (5.14° ± 2.48° and 4.95° ± 2.45°, respectively) (p = 0.036) and L5–left ilium (5.19° ± 2.34° and 4.99° ± 2.31°) (p = 0.022). Last, results of the axial compression testing at all measured points were not statistically different among reconstructions.CONCLUSIONSThe addition of a transverse bar in Model 2 offered no biomechanical advantage. Although the implementation of 4 iliac screws and 4 rods conferred a definitive kinematic advantage in Model 3, that model was associated with significantly restricted lumbopelvic ROM.
Microlobectomy: A Novel Form of Endoscopic Lobectomy
Dunning, Joel , Elsaegh, Mohamed, Nardini, Marco , Gillaspie, Erin A. , Petersen, René Horsleben , Hansen, Henrik Jessen, Helsel, Bryan S., Naase, Hatam, Kornaszewska, Malgorzata, Will, Malcolm , Wigle, Dennis A. , Walker, W. S. G. , Blackmon, Shanda

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | August 1, 2017 | Volume: 12 | Issue: 4 | Pages: 247-253

10.1097/imi.0000000000000394 | PMID 28763351 Get It

Objective Microlobectomy is a novel form of videoscopic-assisted thoracic surgery lobectomy. Strict inclusion criteria consist of the following: no intercostal incisions greater than 5 mm, 12 mm subxiphoid port, subxiphoid removal of the specimen, total endoscopic technique with CO 2 insufflation, vision through a 5-mm camera, stapling via the subxiphoid port, or with 5-mm stapling devices. Methods The combined early experiences of six hospitals from three countries were combined from September 2014 to May 2016. During that time, the study represents a consecutive cohort study of this technique. Results Seventy-two patients underwent microlobectomy. The median (range) age was 66 (27–82). Half of the patients were female. There were 48 right-sided resections and 24 on the left. There were four segmental resections and there was one right pneumonectomy. Four operations were performed robotically (with 8-mm intercostal incisions). The median (range) operative time was 180 (94–285) minutes and the blood loss was 118 (5–800) mL. There were three conversions to thoracotomy and two conversions to videoscopic-assisted thoracic surgery by means of an intercostal utility incision to complete the operation. The median (range)length of stay was 3(1–44) days and 30 patients (42%) when home by day 2 and 16 patients (22%) were discharged on day 1. There were no deaths. Five patients (7%) had a prolonged airleak. There were no wound infections and there was one incisional hernia. Conclusions We believe that microlobectomy is an interesting novel form of videoscopic-assisted thoracic surgery lobectomy and has several theoretical advantages. We have presented our early results and hope that this will stimulate others to investigate this type of videoscopic-assisted thoracic surgery lobectomy further.
Proliferation and Differentiation Characteristics of Normal Human Squamous Mucosal Cells of the Upper Aerodigestive Tract
Kasperbauer, Jan L. , Neel, H. Bryan, Scott, Robert E.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | July 27, 2017 | Volume: 99 | Issue: 1 | Pages: 29-37

10.1177/000348949009900105 | PMID 2403769 Get It

Normal human squamous mucosal cells of the soft palate, buccal surface, epiglottis, hypopharynx, floor of the mouth, and tongue were cultured in vitro in serum-free medium. In medium MCDB 153 containing epidermal growth factor, insulin, bovine pituitary extract, and 0.1 or 2.0 mmol/L Ca ** , squamous mucosal cells double every 24 hours. These cells then can be induced to arrest their proliferation reversibly by treatment with transforming growth factor-β or ethionine, and they can irreversibly growth-arrest during senescence or when cultured in growth factor–deficient medium containing 2 mmol/L Ca ** . The latter medium also induces differentiation, as does culture of cells in serum-containing medium. Serum-containing medium furthermore promotes extensive cell stratification and the formation of multilayered squamous mucosal tissue specimens that can be removed intact by Dispase treatment. These specimens represent potential autogenous mucosal grafts that can be used in patients who require reconstructive surgery of the oral cavity and oropharynx. Normal human squamous mucosal cells therefore closely resemble keratinocytes derived from the epidermis in the mechanisms that regulate proliferation and differentiation. This model cell system should facilitate future studies on upper aerodigestive tract squamous mucosal cell physiology and pathophysiology.
An analysis of the Arc CHECK ‐ MR diode array's performance for ViewRay quality assurance
Ellefson, S.T., Culberson, Wesley S. , DeWerd, Larry A. , Bayouth, John E. , Ellefson, Steven T, Bednarz, Bryan P.

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 6, 2017 | Volume: 18 | Issue: 4 | Pages: 161-171

10.1002/acm2.12107 | PMID 28681448 Get It

Abstract The Arc CHECK ‐ MR diode array utilizes a correction system with a virtual inclinometer to correct the angular response dependencies of the diodes. However, this correction system cannot be applied to measurements on the ViewRay MR ‐ IGRT system due to the virtual inclinometer's incompatibility with the ViewRay's multiple simultaneous beams. Additionally, the Arc CHECK 's current correction factors were determined without magnetic field effects taken into account. In the course of performing ViewRay IMRT quality assurance with the Arc CHECK , measurements were observed to be consistently higher than the ViewRay TPS predictions. The goals of this study were to quantify the observed discrepancies and test whether applying the current factors improves the Arc CHECK 's accuracy for measurements on the ViewRay. Gamma and frequency analysis were performed on 19 ViewRay patient plans. Ion chamber measurements were performed at a subset of diode locations using a PMMA phantom with the same dimensions as the Arc CHECK . A new method for applying directionally dependent factors utilizing beam information from the ViewRay TPS was developed in order to analyze the current Arc CHECK correction factors. To test the current factors, nine ViewRay plans were altered to be delivered with only a single simultaneous beam and were measured with the Arc CHECK . The current correction factors were applied using both the new and current methods. The new method was also used to apply corrections to the original 19 ViewRay plans. It was found the Arc CHECK systematically reports doses higher than those actually delivered by the ViewRay. Application of the current correction factors by either method did not consistently improve measurement accuracy. As dose deposition and diode response have both been shown to change under the influence of a magnetic field, it can be concluded the current Arc CHECK correction factors are invalid and/or inadequate to correct measurements on the ViewRay system.
Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry
Merola, Aristide , Fasano, Alfonso , Hassan, Anhar , Ostrem, Jill L. , Contarino, Maria Fiorella , Lyons, Mark , Wolf, Marc E. , Klassen, Bryan T. , Rootselaar, Anne‐Fleur van , Regidor, Ignacio , Ondo, William G. , Guridi, Jorge , Volkmann, Jens , Shukla, Aparna Wagle , Mandybur, George, Okun, Michael S. , Witt, Karsten , Starr, Philip A. , Deuschl, Günther , Espay, Alberto J , Krauss, Joachim Kurt , Duker, Andrew , Espay, Alberto J. , Deuschl, Günther , Okun, Michael S

Mayo Clinic

Movement Disorders | June 20, 2017 | Volume: 32 | Issue: 8 | Pages: 1240-1244

10.1002/mds.27082 | PMID 28631862 Get It

AbstractBackgroundWe report the accumulated experience with ventral intermediate nucleus deep brain stimulation for medically refractory orthostatic tremor.MethodsData from 17 patients were reviewed, comparing presurgical, short‐term (0‐48 months), and long‐term (≥48 months) follow‐up. The primary end point was the composite activities of daily living/instrumental activities of daily living score. Secondary end points included latency of symptoms on standing and treatment‐related complications.ResultsThere was a 21.6% improvement (P = 0.004) in the composite activities of daily living/instrumental activities of daily living score, which gradually attenuated (12.5%) in the subgroup of patients with an additional long‐term follow‐up (8 of 17). The latency of symptoms on standing significantly improved, both in the short‐term (P = 0.001) and in the long‐term (P = 0.018). Three patients obtained no/minimal benefit from the procedure.ConclusionsDeep brain stimulation of the ventral intermediate nucleus was, in general, safe and well tolerated, yielding sustained benefit in selected patients with medically refractory orthostatic tremor. © 2017 International Parkinson and Movement Disorder Society
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Springer, Bryan D. , Dasa, Vinod , George, Michael , Gewurz‐Singer, Ora, Giles, Jon T. , Johnson, Beverly , Mandl, Lisa A. , Mont, Michael A. , Sculco, Peter K. , Sporer, Scott M. , Stryker, Louis S., Turgunbaev, Marat, Brause, Barry D. , Gililland, Jeremy M. , Goodman, Mark A. , Hurley-Rosenblatt, Arlene, Kirou, Kyriakos A. , Losina, Elena , MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Miller, Amy S., Singh, Jasvinder A. , Yates, Adolph J. , Losina, Elena , George, Michael , Losina, Elena , Singh, Jasvinder A , Goodman, Susan M. , Guyatt, Gordon , Abdel, Matthew P. , Lee, Steve C. , Chen, Antonia F. , Michaud, Kaleb D. , Mikuls, Ted R. , Losina, Elena , Giles, Jon T , Kirou, Kyriakos A

Mayo Clinic

Arthritis Care & Research | June 16, 2017 | Volume: 69 | Issue: 8 | Pages: 1111-1124

10.1002/acr.23274 | PMID 28620917 Get It

Objective This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence‐based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Methods A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi‐step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. Results The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease‐modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low‐ or moderate‐quality evidence. Conclusion This guideline should help decision‐making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high‐quality direct randomized controlled trial data.
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Springer, Bryan D. , Dasa, Vinod , George, Michael , Gewurz‐Singer, Ora, Giles, Jon T. , Johnson, Beverly , Mandl, Lisa A. , Mont, Michael A. , Sculco, Peter K. , Sporer, Scott M. , Stryker, Louis S., Turgunbaev, Marat, Brause, Barry D. , Gililland, Jeremy M. , Goodman, Mark A. , Hurley-Rosenblatt, Arlene, Kirou, Kyriakos A. , Losina, Elena , MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Miller, Amy S., Singh, Jasvinder A. , Yates, Adolph J. , Losina, Elena , George, Michael , Losina, Elena , Singh, Jasvinder A , Goodman, Susan M. , Guyatt, Gordon , Abdel, Matthew P. , Lee, Steve C. , Chen, Antonia F. , Michaud, Kaleb D. , Mikuls, Ted R. , Losina, Elena , Giles, Jon T , Kirou, Kyriakos A

Mayo Clinic

Arthritis & Rheumatology | June 16, 2017 | Volume: 69 | Issue: 8 | Pages: 1538-1551

10.1002/art.40149 | PMID 28620948 Get It

ObjectiveThis collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence‐based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA).MethodsA panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi‐step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences.ResultsThe guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease‐modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low‐ or moderate‐quality evidence.ConclusionThis guideline should help decision‐making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high‐quality direct randomized controlled trial data.
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Glubb, Dylan M. , Group, the AGO Study, Johnatty, Sharon E. , Quinn, Michael C. , O’Mara, Tracy A. , Gao, Bo , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, Benı́tez, Javier , García, María J. , Goodman, Marc T. , Thompson, Pamela J., Dörk, Thilo , Modungo, Francesmary, Moysich, Kirsten B. , Heitz, Florian , Pfisterer, Jacobus , Hillemanns, Peter , Lester, Jenny, Goode, Ellen L. , Cunningham, Julie M. , McCauley, Bryan M. , Jensen, Allan , Schildkraut, Joellen M. , Terry, Kathryn L. , Salvesen, Helga B., Webb, Penny M., Grant, Peter J. , Moffitt, Melissa , Høgdall, Claus , Paul, James, Bernardini, Marcus Q. , Tone, Alicia , Huntsman, David, Woo, Michelle, Group, AOCS, DeFazio, Anna , Kennedy, Catherine J. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Webb, Penelope M. , Bowtell, David D.L. , Lambrechts, Diether , Winham, Stacey J. , Fazio, Anna de , Group, the AGO Study, Tyrer, Jonathan P. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Dürst, Matthias , Bois, Andreas du , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Webb, Penny M., Pejovic, Tanja B. , Høgdall, Estrid , Glasspool, Rosalind , Group, AOCS, Pharoah, Paul D.P. , Dörk, Thilo , Lambrechts, Diether , Webb, Penelope M , Hillemanns, Peter , Jensen, Allan , Moysich, Kirsten , Kennedy, Catherine J , O'Mara, Tracy A , Heitz, Florian , Lambrechts, Diether , Quinn, Michael C J , MacGregor, Stuart , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Oncotarget | June 15, 2017 | Volume: 8 | Issue: 39 | Pages: 64670-64684

10.18632/oncotarget.18501 | PMID 29029385 Get It